Two molecular pathways, involving a protease and a receptor and that affect the barrier between the maternal and fetal blood, have been identified in mice.
The maternal-fetal interface ensures the proper exchange of nutrients and waste products between maternal and fetal blood, while shielding the fetus from toxins, excess hormones, and other factors from the mother. One barrier that ensures proper exchange of substances is an embryo-derived epithelium, which separates the maternal and fetal circulation in the placenta.
Previous studies have examined expression of various proteins in the mouse placenta and found the cell surface protease matriptase and its partner protease prostatin, both of which are known to function in epithelial barriers in other tissues. Co-localized with these proteases is PAR-2 (protease-activated receptor-2; also known as F2rl1 or coagulation factor II [thrombin] receptor-like 1), a G- protein-coupled protein receptor known to be stimulated by matriptase. In the new study, Roman Szabo et al. find that matriptase/prostatin and PAR-2 have redundant, overlapping functions in the placental epithelium.
The researchers examined mice with deficiencies in both matriptase and PAR-2, and showed that the mice did not survive to term. They also examined matriptase-deficient mice heterozygous for PAR-2, and these mice showed diminished survival. There were no visible abnormalities in the embryo proper in these mutant animals. Instead, several observations suggested that the defects in the mutant mice appeared to be in the extraembryonic placenta. In particular, in PAR-2-deficient mice, in which matriptase was conditionally deleted only from the embryo proper, prenatal development and survival were not affected. Instead, the placentas had reduced vascularization, and the placental barrier appeared compromised.
Genetic inactivation of either matriptase or PAR-2 alone resulted in increased placental permeability, a defect that was more pronounced in mice deficient in PAR-2 and heterozygous for matriptase, and in mice deficient in matriptase but heterozygous for PAR-2-with the leakiest placenta being observed in the double knockout.
Exactly how the PAR-2 and matriptase pathways affect the placenta remains to be uncovered, but the researchers did show that the double-mutant had reduced expression of the tight junction protein claudin-1. A peptide coating human sperm defends against microbes and enhances mobility, according to a new study. The findings suggest that the peptide, b-defensin 1, may boost fertility in men suffering from infertility.
Defensins are best known as microbe-fighting peptides throughout the body. More recent studies have shown that defensins play a role in sperm, promoting functions such as motility and capacitation [1] , and many of these specialized defensins are found only in the male reproductive tract. b-Defensin 1 is found throughout the body, on almost every epithelial surface, and more recent studies have shown that it is present in seminal plasma and ejaculated spermatozoa (Fig.  1) .
In the new study [2] , Hsiao Chang Chan and colleagues examined b-defensin 1 in men with reduced sperm motility (a common cause of infertility) and with leukocytospermia (the presence of leukocytes in semen), a condition that may reflect seminal tract infection. They found that men in both groups had relatively low levels of b-defensin 1, compared with unaffected men, and that treatment of their sperm in vitro with recombinant b-defensin 1 restored sperm quality, as well as egg-penetrating capability. Moreover, they found that interfering with b-defensin 1 activity in sperm from unaffected men decreased sperm mobility and antibacterial activity.
The researchers delved into how b-defensin 1 operates, showing that it binds to a receptor on the surface of sperm, CCR6. Once bound to CCR6, b-defensin 1 triggers the influx of calcium into sperm, promoting motility. Binding to CCR6 was also required for sperm to fend off microbes.
The findings suggest that exposing sperm to recombinant-bdefensin 1 may offer a potential treatment for common forms of infertility.
